Pre-eclampsia is a pregnancy related syndrome that contributes to maternal and perinatal mortality and morbidity in India. The FIGO guidelines have recommended where possible 1st Trimester prediction of pre-term Pre-eclampsia to enable Aspirin treatment for prevention.

However, today, most women who develop pre-eclampsia are identified only when symptoms have developed in 2^nd or 3^rd Trimester. Assessment at this time is challenging and there is an opportunity to identify potential tools which may support that process.

Therefore, in association with many of the eminent from the medical sector, PerkinElmer invites all the interested participants to attend the e - conference on September 22, 2020 for the duration of 2hours.

This e-conference will provide an insight into the experiences of one laboratory who offer a 1^st Trimester prediction panel to their physicians. The focus will then shift to management of women who present with symptoms in 2^nd and 3^rd Trimester, with an emphasis on the potential role of point of care tests, to identify those women most at risk of adverse outcomes whilst reducing the need for unnecessary hospitalization.

There is no participation fee.

Participants are required to register and attend the complete webinar, if they wish to have e-Certificate.